IPP Bureau
Thyrocare Technologies posts Q4 FY24 consolidated PAT at Rs. 17.78 Cr
By IPP Bureau - May 15, 2024
The company has posted net profit of Rs.70.76 crores for the Financial Year ended March 31, 2024
Gujarat Themis Biosyn posts Q4 FY24 PAT at Rs. 15.88 Cr
By IPP Bureau - May 15, 2024
The company has posted net profit of Rs. 59.16 crores for the Financial Year ended March 31, 2024
Merck discontinues Phase 3 KeyVibe-010 trial of coformulation of Vibostolimab and Pembrolizumab
By IPP Bureau - May 14, 2024
Data showed that the primary endpoint of recurrence-free survival (RFS) met the pre-specified futility criteria
AbbVie and Gilgamesh Pharmaceuticals collaborate to develop next-gen therapies for psychiatric disorders
By IPP Bureau - May 14, 2024
Collaboration to leverage AbbVie's psychiatry expertise and Gilgamesh's innovative research platform to develop next-generation neuroplastogens for the treatment of psychiatric disorders
Moderna update on investigational RSV vaccine
By IPP Bureau - May 14, 2024
U.S. FDA has informed Moderna that due to administrative constraints, the agency will not complete its review of mRNA-1345 by the PDUFA date of May 12, 2024
Lonza reports softer performance in Q1 2024
By IPP Bureau - May 14, 2024
Outlook 2024 remains flat CER sales growth and CORE EBITDA margin of high 20s
Bayer Q1 2024 net income drops 8.2% to € 2 billion
By IPP Bureau - May 14, 2024
EBITDA before special items falls 1.3 percent to € 4.41 billion
Coveris invests over €8 million in production capacity
By IPP Bureau - May 14, 2024
Investing considerably in production capacity for medical device packaging at its Rohrdorf and Halle sites in Germany
Sanofi India posts Q1 CY24 PAT at Rs. 136.6 Cr
By IPP Bureau - May 14, 2024
Sanofi India has reported total income of Rs. 738.9 crores during the period ended March 31, 2024
Zydus receives final approval from USFDA for Dexamethasone Tablets
By IPP Bureau - May 13, 2024
Dexamethasone Tablets USP, 1 mg had annual sales of US$ 1.8 mn in the United States (IQVIA MAT March 24)
Briefs: Lupin and Aurobindo Pharma
By IPP Bureau - May 13, 2024
Lupin updates on shipment of Mirabegron ER Tablets
Novartis India posts Q4 FY24 net profit lower at Rs. 14.68 Cr
By IPP Bureau - May 12, 2024
Novartis India has reported total income of Rs. 91.59 crores during the period ended March 31, 2024
Cipla posts Q4 FY24 consolidated PAT at Rs. 939.04 Cr
By IPP Bureau - May 11, 2024
The company has posted net profit of Rs. 4,121.55 crores for the Financial Year ended March 31, 2024
Dr. Lal PathLabs posts Q4 FY24 consolidated PAT at Rs. 84.5 Cr
By IPP Bureau - May 11, 2024
The company has posted net profit of Rs.357.7 crores for the Financial Year ended March 31, 2024
